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ABSTRACT. The discovery of molecules that bind tightly
and selectively to desired proteins continues to drive
innovation at the interface of chemistry and biology. This
paper describes the binding of human insulin by the synthetic receptor cucurbit[7]uril (Q7) in vitro. Isothermal
titration calorimetry and fluorescence spectroscopy experiments show that Q7 binds to insulin with an equilibrium association constant of 1.5 x 106 M-1 and with 50100-fold selectivity versus proteins that are much larger
but lack an N-terminal aromatic residue, and >1000-fold
selectivity versus an insulin variant lacking the Nterminal phenylalanine (Phe) residue. The crystal structure of the Q7•insulin complex shows that binding occurs
at the N-terminal Phe residue and that the N-terminus
unfolds to enable binding. These findings suggest that
site-selective recognition is based on the properties inherent to a protein terminus, including the unique chemical epitope presented by the terminal residue and the
greater freedom of the terminus to unfold, like the end of
a ball of string, to accommodate binding. Insulin recognition was predicted accurately from studies on short peptides and exemplifies an approach to protein recognition
by targeting the terminus.
Living systems present a highly complex array of molecular surfaces that vary in size, shape, polarity, organization
and solvation, and yet each molecule finds its target destination with high fidelity. The weak intermolecular forces
(e.g., coulombic, dispersive, and solvophobic) that direct
these events are well understood in principle.1-3 In practice,
however, the design of synthetic compounds to recognize
desired protein targets presents persistent challenges en
route to pharmaceuticals, medical diagnostics, and other
tools for biochemistry and chemical biology. So-called “rational” approaches to this problem use detailed knowledge
of the structure of a target to aid in the design of a complementary molecule.4-6 Although high-resolution structures are
available for a number of protein targets, the precise structure of the surface of a protein and the surrounding solvent
remains difficult to predict from the genetically encoded
sequence of amino acids or from homology modeling.
Therefore, general design principles for sequence-based
recognition of folded proteins do not currently exist. By contrast, numerous groups have reported on the sequencespecific recognition of short peptides in aqueous solution by
synthetic receptors.7-17 Short peptides are more practical
than proteins for structure-activity studies of molecular
recognition because they are less expensive, are easier to
modify, and in many cases their structures are predictably
folded/unfolded. Therefore, strategies for translating known
approaches of peptide recognition into protein recognition

would be exceptionally valuable. Here we show that the
synthetic receptor cucurbit[7]uril (Q7, Figure 1) binds to the
N-terminal phenylalanine (Phe) of human insulin, and that
this recognition enables Q7 to bind more tightly to insulin
than to proteins lacking an N-terminal aromatic residue.
Equilibrium binding studies and X-ray crystallography

Figure 1. Amino acid sequences of the insulins and model
peptides used in this study, and the chemical formula of Q7.

reveal the molecular basis for recognition and show how the
properties of a protein terminus are well suited to siteselective recognition.
Q7 is the seven-membered macrocycle in the cucurbit[n]uril (Qn) family of water-soluble, synthetic receptors,
which have gained importance for their capacity to bind
small guests very tightly and selectively in aqueous solution.18-20 The nonpolar interior and carbonyl-lined portals of
Qn receptors work in concert to bind organic cations by
including the hydrophobic portion of the guest within the
apolar cavity and stabilizing the cationic group(s) with the
portal oxygens. This cooperation between cavity and portal
has proved ideal for binding to short peptides with an Nterminal phenylalanine (Phe), tryptophan (Trp), or tyrosine
(Tyr), in a sequence-specific fashion.14-17,21 In focused
structure-activity studies with Q7 and Q8,15,17 all peptides
had a single aromatic group and an N-terminal ammonium
group, but only those with an N-terminal aromatic residue,
which fixes both groups in close proximity, were bound selectively by Q7 and Q8. Therefore, the terminus provided a
binding site that is structurally unique at the level of a single-residue and thus known from the sequence of amino
acids. On the basis of these studies we predicted that a Qn
receptor should bind selectively to an N-terminal aromatic
residue versus all other surface-exposed aromatic residues

on a folded protein and thus provide a mechanism for sitespecific protein recognition. In the present study, human
insulin was identified as a desirable model on which to test
this hypothesis because it has a rare Phe residue at the Nterminus of its B-chain (i.e., PheB1), it has been thoroughly
characterized, and it is stably folded under ambient conditions.22
Isothermal titration calorimetry (ITC) experiments revealed
that Q7 binds to recombinant human insulin 1 in a 1:1 stoichiometric ratio with an equilibrium association constant
(Ka) value of 1.5 x 106

Figure 2. (a) Representative ITC data for the titration of Q7 to
native human insulin 1. The top plot of power versus time was
integrated to yield the bottom plot of molar enthalpy versus the
ratio of Q7:insulin. The gray data points in the bottom plot are
for the analogous experiment on variant insulin 2, showing no
measurable binding. (b) Bar plot of the equilibrium association
constants of analytes 1 – 5 in complex with Q7. Error bars are
standard deviations from at least three measurements. The ITC
technique has a practical lower limit of 103 M-1.

M-1 (Figure 2). Although we anticipated binding at the Phe B1
position, insulin also has on its surface two Phe and four Tyr
residues, all of which are possible binding sites. The series
of compounds 2-5 (Figure 1) was designed to probe the
location of binding. Protein 2 is a variant of human insulin
with glutamic acid (Glu) at positions B1 and B27 (i.e., Glu B1,
GluB27).23,24 Peptides 3-5 are models of the N-terminal Phe
(3), non-terminal Phe (4), and non-terminal Tyr (5) residues
on the surface of insulin.
ITC measurements (Figure 2 and Supporting Information)
showed no measurable binding of Q7 to variant insulin 2,
which has no N-terminal Phe, and thus a decrease in association constant by more than three orders of magnitude
compared to native insulin 1. This result makes a strong
case for PheB1 as the site of binding. Positive control peptide 3 (Ka = 2.8 x 106 M-1), which has an N-terminal Phe,

binds to Q7 with similar affinity as native insulin 1. Peptides
4 (2.2 x 104 M-1) and 5 (2.7 x 103 M-1) were bound less tightly than peptide 3 by two and three orders of magnitude,
respectively, showing that non-terminal Phe and Tyr residues are possible, albeit weak, sites of binding for Q7.
Therefore, we were surprised that Q7 showed no measurable affinity for variant insulin 2, which suggests that the two
non-terminal Phe and four non-terminal Tyr residues on the
surface of 2 are significantly less accessible to binding than
the analogous residues in peptides 4 and 5.
We sought structural evidence to support the ITC data
and to explore a molecular basis for recognition. Toward
this end, we determined the crystal structure of the Q7•1
complex (Figure 3). The asymmetric unit of the crystal (Figure 3a) contains two insulin molecules (1a and 1b) and one
molecule of Q7, which is associated with insulin 1a at the Nterminus of the B chain. Akin to previously reported structures of Q8 in complex with Phe-Gly-Gly and Trp-Gly-Gly,15
the Q7•insulin structure shows the aromatic sidechain of
PheB1 included within the cavity of Q7. In addition, Val B2 and
AsnB3 contribute weak stabilizing interactions by contacting
atoms of the Q7 exterior. Overall, the binding of Q7 buries
approx. 200 Å2 of insulin’s solvent-accessible surface area.25 The presence of Q7-bound insulin 1a and unbound
insulin 1b in the asymmetric unit of the crystal allows us to
study perturbations to the structure of insulin upon binding
to Q7. Overall, the structures of 1a and 1b are strikingly
similar, with a root mean square deviation (RSMD) of 0.37 Å
over 35 alpha carbons. The largest deviations are observed
at the B1-B4 residues of 1a, which unfold from the surface
of the protein to accommodate Q7 (Figure 3b).
These results corroborate the calorimetric data and provide a structural basis for recognition at the N-terminus of
the B chain of insulin. As observed with small peptides, 15
stable binding requires the simultaneous inclusion of the
hydrophobic sidechain of PheB1 within the cavity of Q7 and
interaction of the N-terminal ammonium group with the portal oxygens of Q7. The PheB1 residue therefore presents a
unique binding epitope comprising the aromatic sidechain
and the N-terminal ammonium group, which cannot exist
anywhere else on the protein. Moreover, the ability of the
insulin N-terminus to partially unfold may be critical to binding in the sterically demanding context of a folded protein.
The singular connection of the terminal residue to the protein, like the end of a ball of string, facilitates the adoption of
a fully solvent-exposed, random-coil structure, akin to short
peptides. This result is likely not unique to insulin because
protein termini are typically solvent-exposed, more so than
charge alone would predict.26

Figure 3. Crystal structure of the Q7•1 complex. (a) Asymmetric unit of the crystal, with the two molecules of insulin, 1a (green) and
1b (black), rendered as ribbons and the associated Q7 as sticks. The solvent-accessible surface is shown as semi-transparent to
reveal the overall shape of the complex. The PheB1 position of 1a, which is bound inside Q7, is rendered as space-filling, with carbon
in green, oxygen in red, and nitrogen in blue; the N-terminal nitrogen is the blue sphere. (b) Superposition of the two insulins illustrates the strong homology between 1a and 1b with clear divergence at the N-terminus of the B-chain. In this image, the PheB1 position of both insulins is rendered as space-filling for comparison.

proteins lacking an N-terminal aromatic residue. A fluorescence indicator displacement assay27 was used to test this
hypothesis. We chose acridine orange because it has relatively little nonspecific association with proteins, it is effective at neutral pH, and its Ka value for Q7 (2.0 x 105 M-1) is
similar yet lower than that of insulin.28 The emission of acridine orange increases when bound to Q7. Therefore, upon
introducing a competitive analyte to a solution containing
the Q7•acridine orange complex, the displacement of acridine orange from Q7 yields a decrease in fluorescence intensity that indicates the binding of analyte (Figure 4a).

Figure 4. Fluorescent indicator displacement assay for insulin.
(a) Decrease in emission intensity upon titrating insulin at 0,
0.5, 1.0, 2.0, 4.0, 8.0, and 16.0 M into a mixture of Q7 (6 M)
and acridine orange (8 M). (b) Fluorescence quenching for a
series of proteins and peptides at 4 M in a mixture of 4 M Q7
and 6 M acridine orange, showing selective binding of native
insulin 1 and positive control peptide 3. Error bars are standard
deviatations from at least three measurements. BSA, bovine
serum albumin; IgG, immunoglobulin G; BCA, bovine carbonic
anhydrase; GGG, peptide Gly-Gly-Gly.

Based on the mechanism of binding established here, we
expected that Q7 would not exhibit high affinity binding to

The fluorescence response for insulin was compared to
compounds 2-5, the peptide Gly-Gly-Gly, and a series of
commercially available blood proteins, including bovine serum albumin (BSA), human immunoglobulin G (IgG), and
bovine carbonic anhydrase (BCA) (Figure 4b). We observed
substantial quenching (55-80%) with insulin 1 and peptide 3
(positive control), but insignificant quenching for the other
analytes (1-5%), which lack an aromatic terminus. This result demonstrates that a single residue can enable the selective binding of insulin versus other proteins by at least
50-100-fold in Ka29 under the conditions used in this study.
We note explicitly, however, that insulin recognition in vivo
would be precluded by (i) its relatively high dissociation
constant (0.67 M) compared to the sub-nM concentrations
of insulin in blood and saliva, (ii) the presence of weak binding proteins (e.g., albumin) at sufficiently high concentrations to effectively compete for binding,30-32 and (iii) the possibility of competition by other peptides and proteins with Nterminal aromatic groups. This paper does not claim to address these challenges pertaining to in vivo applications.
This paper describes an approach to protein recognition
that exploits the unique properties of a protein terminus to
achieve single-site binding that is predictable from the sequence of amino acids. Unlike small molecules that bind
inside protein cavities,5 and unlike natural and synthetic
receptors that bind to large areas on the surfaces of pro-

teins,4 Q7 binds to insulin by incorporating the terminal residue within its cavity. When the terminus unravels from the
surface it becomes fully solvent exposed, thus allowing Q7
to bind to insulin in the same manner as to a short peptide.
This motif is extraordinarily minimal, comprising a small and
structurally simple receptor, a single amino acid residue,
and a binding interface of ~200 Å2. This approach to protein
recognition differs from existing methods, such as genetically engineering polyhistidine (His-tag) or glutathione Stransferase (GST) fusion proteins into target proteins for
affinity chromatography,33 or chemically modifying proteins
with biotin or aminomethylferrocene groups for capture using avidin or Q7,34-36 respectively. In the current study, Q7
binds directly to the native protein sequence, not an engineered or chemically modified sequence, 37 although we
consider these techniques to be complementary. We believe this approach will facilitate the design of receptors for
other proteins as well as the development of techniques for
single-site labeling of proteins and for sensing and separating proteins according to the identity of the terminal residue.
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